our Products

WE ARE TARGETING PAIN AT ITS SOURCE

Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from the postoperative pain to the treatment of acute and chronic pain.

INNOVATIVE DRUG-DELIVERY
TECHNOLOGIES

Transdermal metered dose spray

Virpax® has licensed a patented aerosol-based system that delivers active pharmaceutical ingredients (API) as a Patch-in-a-Can. This proprietary spray formulation delivers the API as a film and can be manipulated to deliver API immediately or over an extended time from 12 to 24 hours.

Convenient

No messy cream or gels that can be rubbed off by clothing or physical contact

Aesthetically appealing

Invisible once applied

Easily optimizable

Use with metered-dose delivery valves

"I feel that a large number of pain patients will prefer the spray over patches and ointment and am really glad to see this new technology that will allow more precise application while using lesser active ingredient."

Sanjay Gupta

President, American Pain Association

Liposomal in Hydrogel encapsulation

Our patented liposomal gel encapsulates a high dose of local anesthetic in hydrogel, cholesterol, and other “GRAS” lipids. A single dose can be injected at the surgical site to provide a prolonged postoperative analgesia effect for up to 96 hours. This may enhance recovery protocols, reduce the length of a patient’s hospital stay post-surgery, and significantly reduce or eliminate the use of opioids.

Prolonged effects

Postoperative analgesia effect for up to 96 hours

Efficient drug-delivery

Fast onset of action and peak analgesic activity in post-operative setting

Improved quality of care

Reduce reliance on opioid pain management; may lead to experience better rehabilitation outcomes

Intranasal spray

Using Molecular Envelope Technology (MET), we are working to enhance enkephalin transport to the brain through an intranasal formulation. This nanotechnology enables metabolically labile peptide molecules, like enkephalin,  to pass through the blood-brain barrier in order to help manage chronic pain. These enkephalin-filled nanoparticals are preloaded into a cartridge with compressed inert gas as a single dose that is compatible with our specialize device. With a simple press of a button, the device releases this powder as a long and thin plume penetrating the olfactory region.

Drug Loaded Nanoparticles

The enkephalin molecule is loaded in nanoparticles

Easy-to-use device

No breath coordination required. Caregiver can administer to an incapacitated person

Blood-brain barrier Bypass

Drug bypasses the blood brain barrier by targeting the olfactory region

We are developing novel products by combining innovative drug compounds with cutting-edge delivery systems. Each product offers its own advantages to the franchise, giving healthcare providers the options and treatment alternatives they seek.

Product overview

DSF100

Topical NSAID spray film

STATUS: Capital funding

TARGET MARKET

Topical treatment for acute musculoskeletal pain

DELIVERY SYSTEM

Metered dose spray film

Benefits

  • Faster drying, less messy, comparable skin absorption, and improved patient compliance
  • Better adhesiveness with direct skin contact
  • Better accessibility to active joints: wrists, ankles, knees and elbows
  • Improved patient compliance that could result in enhanced therapeutic outcomes

NEW DRUG APPLICATION (NDA)

As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue a 505(b)(2) New Drug Application for DSF100.

LBL100

Long-acting local anesthetic/liposomal-gel

STATUS: Capital funding

TARGET MARKET

Post surgical knee and hip pain

DELIVERY SYSTEM

Liposomal in hydrogel encapsulation

Benefits

  • Single dose infiltration into the surgical site
  • Prolonged postoperative analgesia effect up to 96 hours
  • May eliminate the need for opioids and catheters after surgery
  • May reduce associated costs and length of patient stay
  • May significantly reduce or eliminate opioids

NEW DRUG APPLICATION (NDA)

As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue a 505(b)(2) New Drug Application for LBL100.

NES100

Endogenous enkephalin intranasal spray

STATUS: Grant

TARGET MARKET

Treatment of chronic pain

DELIVERY SYSTEM

Endogenous enkephalin intranasal spray

Benefits

  • Enkephalin prodrug formulation that targets delta receptors instead of mu receptors that are responsible for the majority of undesirable side effects associated with narcotics
  • Analgesic potential to manage chronic pain without the concerns of opioid tolerance, withdrawal, respiratory depression, or euphoria

RES202

Long-acting naloxone-naltrexone/liposomal-gel

STATUS: Grant and Research

TARGET MARKET

Rapid-onset and long-lasting opioid antagonist

DELIVERY SYSTEM

Intramuscular auto-injection

Benefits

  • May reverse opioid side effects up to 96 hours
  • Rapid and enduring rescue and reversal of opioid overdose
  • Intramuscular rescue auto injection is more effective at reversing respiratory depression cause by opioid overdose

Product Pipeline

Corporate headquarters

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

Phone   484-875-3195

Email     info@virpaxpharma.com

© Virpax® Pharmaceuticals. All Rights Reserved.

INNOVATIVE
DRUG-DELIVERY
TECHNOLOGIES

Transdermal metered dose spray

Virpax® has licensed a patented aerosol-based system that delivers active pharmaceutical ingredients (API) as a Patch-in-a-Can. This proprietary spray formulation delivers the API as a film and can be manipulated to deliver API immediately or over an extended time from 12 to 24 hours.

Liposomal in Hydrogel encapsulation

Our patented liposomal gel encapsulates a high dose of local anesthetic in hydrogel, cholesterol, and other “GRAS” lipids. A single dose can be injected at the surgical site to provide a prolonged postoperative analgesia effect for up to 96 hours. This may enhance recovery protocols, reduce the length of a patient’s hospital stay post-surgery, and significantly reduce or eliminate the use of opioids.

Intranasal spray

Using Molecular Envelope Technology (MET), we are working to enhance enkephalin transport to the brain through an intranasal formulation. This nanotechnology enables metabolically labile peptide drugs to pass the blood brain barrier in order to help manage chronic pain.